Postoperative Management of Medullary Thyroid Carcinoma

Immediate Postoperative Hormone Management

The American College of Endocrinology recommends levothyroxine replacement therapy to maintain TSH in the normal range (0.5-2.0 mIU/L) after total thyroidectomy for medullary thyroid carcinoma without known metastatic disease, as TSH suppression is contraindicated because MTC cells lack TSH receptors 1, 2
Levothyroxine should be started immediately after surgery for replacement purposes only, not for TSH suppression, with a target TSH of 0.5-2.0 mIU/L (normal range) 1, 2
MTC arises from parafollicular C cells that do not express TSH receptors, making TSH suppression both ineffective and potentially harmful 1, 2

The National Comprehensive Cancer Network recommends measuring basal serum calcitonin and CEA at 2-3 months postoperatively, as these markers are the cornerstone of MTC follow-up and dictate all subsequent management decisions 3, 4, 1, 2
If calcitonin is undetectable after provocative testing, no additional diagnostic imaging is indicated, and repeat serum calcitonin every 6 months for the first 2-3 years, then measure annually thereafter 5, 2
If calcitonin is detectable but <150 pg/mL, limit evaluation to careful neck ultrasound examination only, and continue monitoring calcitonin every 6 months initially 5, 2
If basal calcitonin is >150 pg/mL, screen for distant metastases with comprehensive cross-sectional imaging, including contrast-enhanced CT of neck and chest 5, 2, 3, 4

The American Thyroid Association recommends not administering radioactive iodine (RAI) for MTC, as it is completely ineffective and contraindicated, since MTC does not concentrate iodine because it arises from C cells, not follicular cells 1, 2

The National Comprehensive Cancer Network recommends considering adjuvant external beam radiation therapy in highly selected cases, such as gross extrathyroidal extension (T4a or T4b) with positive margins after resection, or moderate- to high-volume disease in central or lateral neck lymph nodes with extranodal soft tissue extension 6, 3, 4
Standard dosing when used is 40 Gy in 20 fractions to cervical, supraclavicular, and upper mediastinal nodes, with 10 Gy boost in 5 fractions to thyroid bed 6, 3, 4

The European Society for Medical Oncology recommends surgery as the primary treatment for resectable locoregional recurrence, with reoperation carrying higher complication rates but may achieve biochemical cure in 20-40% of carefully selected patients 5, 4
For metastatic disease, balance the often slow rate of tumor progression against limited efficacy and toxicities of available therapies, and consider vandetanib (FDA-approved) for patients with locally advanced/metastatic MTC and progressive disease 5

Never suppress TSH below normal range in MTC patients, as this provides no benefit and increases cardiovascular and bone risks 1, 2
Do not order RAI therapy or whole body scans, as these are completely ineffective in MTC 1, 2
Do not pursue extensive imaging when calcitonin is <150 pg/mL, and limit to neck ultrasound only to avoid unnecessary radiation exposure and cost 5, 2